A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded an increase of 5.69%. However, over the last six months, the performance has been stronger by -6.32%. The price of BMY increased 6.50% over the last 30 days. And in the last five days, it has surged by 5.12%.
Bristol-Myers Squibb Co.’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $71.07 on 04/06/23, and the lowest price during the same period was recorded at $47.58 on 02/06/24.
52-week price history of BMY Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Bristol-Myers Squibb Co.’s current trading price is -23.69% away from its 52-week high, while its distance from the 52-week low is 13.98%. The stock’s price range over this timeframe has been between $47.58 and $71.07. The shares of the Healthcare sector company recorded a trading volume of approximately 13.51 million for the day, which was comparatively lower than the average daily volume of 16.72 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Bristol-Myers Squibb Co. (BMY) has experienced a quarterly rise of 5.90% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 109.66B and boasts a workforce of 34100 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 50.85, with a change in price of +3.10. Similarly, Bristol-Myers Squibb Co. recorded 16,171,742 in trading volume during the last 100 days, posting a change of +6.06%.
BMY’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for BMY stands at 1.41. Similarly, the long-term debt-to-equity ratio is also 1.30.
BMY Stock Stochastic Average
The raw stochastic average for Bristol-Myers Squibb Co. over the last 50 days is presently at 89.20%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 82.48%. Further, the company’s Stochastic %K and %D values for the last 20 days were 64.26% and 52.59%, respectively.
